Zhanwen Huang

Dr. Zhanwen Huang


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LCLiming Chen
Liming Chen
XZXiaolin Zhong
Xiaolin Zhong
LLLimin Li
Limin Li
XLXue Li
Xue Li
YLYa Liu
Ya Liu
ZHZhanwen Huang
Zhanwen Huang

6 September 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YLYa Liu
Ya Liu
HDHaoyuan Ding
Haoyuan Ding
JCJianpeng Cao
Jianpeng Cao
GLGuangfu Liu
Guangfu Liu
YCYue Chen
Yue Chen
ZHZhanwen Huang
Zhanwen Huang
Purpose: To investigate the feasibility of [68Ga]Ga-FAPI PET/CT in brain tumor imaging and to compare it with [18F]F-FDG PET/CT.Methods: 25 patients with MRI-suspected brain tumors were included in the study. They underwent whole body [18F]F-FDG PET/CT and [68Ga]Ga-FAPI PET/CT and brain scans. The target-to-background ratio (TBR) of brain tumors was calculated with the background of surrounding normal brain tissues uptake. The SUVmax and TBR of [18F]F-FDG PET/CT and [68Ga]Ga-FAPI PET/CT were compared. Additionally, the correlation between the uptake of the tracer by lesions with the greatest diameter of the lesion, the breadth of the oedema band, and the enhancement scores of the MRI enhancement scans was analyzed.Result: [68Ga]Ga-FAPI PET/CT was superior to [18F]F-FDG PET/CT for lesion detection, especially for brain metastases. Among gliomas, only high-grade gliomas uptake [68Ga]Ga-FAPI. Compared with [18F]F-FDG PET/CT, [68Ga]Ga-FAPI PET/CT had a lower SUVmax but a significantly better TBR. On [68Ga]Ga-FAPI PET/CT, the TBR may be associated with brain tumor blood-brain barrier disruption.Conclusions: [68Ga]Ga-FAPI PET/CT is a promising imaging tool for the assessment of brain tumors. Lack of physiological uptake of [68Ga]Ga-FAPI in normal brain parenchyma results in high TBR values, leading to better visualization of lesions and contributing to subsequent targeted therapy studies.Advances in knowledge: Clinical utility of [68Ga]Ga-FAPI PET/CT in brain tumors remains unclear, and there aren’t many similar studies in the literature. We evaluated the role of [68Ga]Ga-FAPI PET/CT in diagnosing brain tumors.

30 April 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
RTRanbie Tang
Ranbie Tang
JPJingguang Pu
Jingguang Pu
ZHZhanwen Huang
Zhanwen Huang

30 April 2024 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
ZWZibei Wan
Zibei Wan
WWWei Wang
Wei Wang
YCYue Chen
Yue Chen
WZWenlu Zheng
Wenlu Zheng
ZHZhanwen Huang
Zhanwen Huang
Rhabdoid meningioma is a rare subtype of meningioma and has a poor prognosis. Herein, we reported a patient of rhabdoid meningioma with multiple liver, pancreas, and bone metastases, who received 177Lu-FAP-2286 therapy. After 1 treatment cycle, 68Ga-FAP-2286 PET/CT revealed partial remission of the lesions.

1 October 2012 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
LCLiang Cai
Liang Cai
YCYue Chen
Yue Chen
ZHZhanwen Huang
Zhanwen Huang
A 66-year-old woman had fever, rash, and joint pain. Physical examination revealed multiple enlarged lymph nodes. A possibility of lymphoma was considered and FDG PET/CT was performed, which demonstrated elevated FDG activity not only in many lymph nodes but also in the spleen and liver. However, adult-onset Still disease was diagnosed, and the patient responded well to therapy.

30 January 2024 in British Journal of Radiology
Verified
Journal Article
Closed access
CGChunmei Guo
Chunmei Guo
YLYa Liu
Ya Liu
HYHaozhou Yang
Haozhou Yang
YXYuxiao Xia
Yuxiao Xia
XLXue Li
Xue Li
ZHZhanwen Huang
Zhanwen Huang
Objectives: As a promising positron emission tomography (PET) tracer, [68Ga]Ga-fibroblast activation protein inhibitor-04([68Ga]Ga-FAPI-04) performs better than 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) at diagnosing primary and metastatic lesions in patients with various types of cancer. We investigated the utility of [68Ga]Ga-FAPI-04 PET/CT for the detection of primary and metastatic lesions in renal cell carcinoma (RCC). [18F]FDG PET/CT were used for comparison. Methods: Twenty-two patients with suspected RCC or recurrent RCC were enrolled in our study. Among these patients, 14 were newly diagnosed with RCC, 3 had recurrent RCC, and 5 were excluded from further analysis due to having benign renal tumours. Seventeen patients with RCC underwent [68Ga]Ga-FAPI-04 PET/CT, and 6 of them also received [18F]FDG PET/CT. The positive detection rates were calculated and compared with those in patients who underwent both scans. Results: Data from 17 patients with RCC (median age: 60.5 years, interquartile range [IQR]: 54-70 years) were evaluated. The positive detection rate of [68Ga]Ga-FAPI-04 PET/CT for RCC was 64.7% (11/17). Lymph node metastases (n = 44), lung metastasis (n = 1), and bone metastasis (n = 1) were detected. Six patients with RCC underwent [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT. [68Ga]Ga-FAPI-04 PET/CT showed a higher positive detection rate than [18F]FDG PET/CT in detecting RCC (83.3% [5/6] vs. 50% [3/6], P = 0.545). Additionally, [68Ga]Ga-FAPI-04 PET/CT has higher SUVmax (3.20 [IQR: 2.91-5.80 vs. 2.71 [IQR: 2.13-3.10], P = 0.116) and tumour-to-background ratio (TBR) values (1.60 [IQR: 1.33-3.67] vs. 0.86 [0.48-1.21], P = 0.028) than [18F]FDG PET/CT. Conclusions: These findings suggest that [68Ga]Ga-FAPI-04 PET/CT has potential value in RCC diagnosis. Further studies are warranted to validate these results. Advances in knowledge: Clinical utility of [68Ga]Ga-FAPI-04 in RCC remains unclear, and there are not many similar studies in the literature. We evaluated the role of [68Ga]Ga-FAPI-04 in diagnosing RCC.